Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$28.77
+5.3%		$31.11
$10.83
▼
$41.14
$3.05B-0.11.34 million shs1.61 million shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$10.76
+5.4%		$9.54
$4.57
▼
$10.84
$527.04M1.22360,593 shs364,915 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
+5.27%+7.15%-11.23%+62.54%+87.18%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
+5.39%+6.32%+12.08%+36.72%+97.43%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$28.77
+5.3%		$31.11
$10.83
▼
$41.14
$3.05B-0.11.34 million shs1.61 million shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$10.76
+5.4%		$9.54
$4.57
▼
$10.84
$527.04M1.22360,593 shs364,915 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
+5.27%+7.15%-11.23%+62.54%+87.18%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
+5.39%+6.32%+12.08%+36.72%+97.43%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.00
Buy$40.7141.52% Upside
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
2.50
Moderate Buy$6.00-44.24% Downside

Current Analyst Ratings Breakdown

Latest AMLX and PBYI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$32.00 ➝ $39.00
10/8/2026
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C+) ➝ Buy (B-)
8/27/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$55.00 ➝ $57.00
8/21/2026
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C) ➝ Hold (C+)
8/19/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$40.00 ➝ $55.00
8/19/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$28.00 ➝ $52.00
8/18/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$30.00 ➝ $42.00
8/18/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$34.00 ➝ $55.00
8/17/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
8/17/2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$24.00 ➝ $30.00
8/7/2026
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingHold (C)
(Data available from 10/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$87.37M36.69N/AN/A$2.78 per share10.35
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$231.24M2.40$0.88 per share12.24$2.59 per share4.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$144.74M-$1.43N/AN/AN/AN/A-52.92%-48.53%11/5/2026 (Estimated)
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$31.11M$0.5220.6976.86N/A11.50%20.76%13.22%11/5/2026 (Estimated)

Latest AMLX and PBYI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.3805N/AN/AN/A$0.06 millionN/A
11/5/2026Q3 2026
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$0.09N/AN/AN/A$57.50 millionN/A
8/6/2026Q2 2026
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.3609-$0.39-$0.0291-$0.39N/AN/A
8/6/2026Q2 2026
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$0.04$0.19+$0.15$0.16$53.00 million$56.50 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/AN/AN/AN/AN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
12.12
12.12
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/A
2.91
2.64

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
61.29%

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
10.90%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
22.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
136111.42 million99.28 millionOptionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
17951.62 million40.16 millionOptionable

Recent News About These Companies

Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
October 20 at 10:41 AM  |  zacks.comhttps://www.zacks.com/stock/news/3011064/will-nerlynx-continue-to-aid-puma-biotechnology-s-top-line-in-q3?cid=cs-stocknewsapi-ft-analyst_blog|quick_take-3011064
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
October 16, 2026  |  zacks.comhttps://www.zacks.com/stock/news/3009801/4-breast-cancer-stocks-to-watch-during-breast-cancer-awareness-month?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-3009801
Puma Biotechnology (NASDAQ:PBYI) Sets New 1-Year High - Here's What Happened
October 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-puma-biotechnology-nasdaq-pbyi-sets-new-1-year-high-heres-what-happened-2026-10-15/
Puma Biotechnology (NASDAQ:PBYI) Sets New 12-Month High - What's Next?
October 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-puma-biotechnology-nasdaq-pbyi-sets-new-12-month-high-whats-next-2026-10-09/
Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200-Day Moving Average - Here's What Happened
October 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-puma-biotechnology-nasdaq-pbyi-shares-cross-above-200-day-moving-average-heres-what-happened-2026-10-09/
Puma Biotechnology stock fell 1.76 percent after award news
October 6, 2026  |  ad-hoc-news.deA
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026  |  marketscreener.comM
Puma Biotechnology (NASDAQ:PBYI) Sets New 1-Year High - Should You Buy?
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-puma-biotechnology-nasdaq-pbyi-sets-new-1-year-high-should-you-buy-2026-09-30/
Puma Biotechnology (NASDAQ:PBYI) Trading Up 5.8% - Here's Why
September 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-puma-biotechnology-nasdaq-pbyi-trading-up-58-heres-why-2026-09-24/
Puma Biotechnology (NASDAQ:PBYI) Hits New 12-Month High - Here's What Happened
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-puma-biotechnology-nasdaq-pbyi-hits-new-12-month-high-heres-what-happened-2026-09-22/
Puma Biotechnology Initiates ALISCA(R)-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
September 18, 2026  |  marketscreener.comM
Puma Biotechnology Advances Alisertib Combo Trial in Small Cell Lung Cancer
September 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/puma-biotechnology-advances-alisertib-combo-trial-in-small-cell-lung-cancer?utm_source=marketbeat.com&utm_medium=referral
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
September 18, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2992104/pbyi-s-alisertib-combo-phase-ii-study-in-small-cell-lung-cancer-begins?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2992104
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
September 17, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260917118471/en/puma-biotechnology-initiates-alisca%c2%ae-lung2-a-phase-ii-trial-of-alisertib-in-combination-with-paclitaxel-for-the-treatment-of-patients-with-advanced-small-cell-lung-cancer/
Insider Selling: Puma Biotechnology (NASDAQ:PBYI) Director Sells $45,500.00 in Stock
September 17, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-pbyi-insider-buying-and-selling-2026-09-17/
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
September 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/puma-biotechnology-present-h-c-201100211.html
Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
September 9, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260909874171/en/puma-biotechnology-to-present-at-h.c.-wainwright%e2%80%99s-28th-annual-global-investment-conference/
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise
September 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4943862-puma-biotechnology-nerlynx-funds-their-potential-next-oncology-franchise
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
August 12, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2973438/is-puma-biotechnology-pbyi-a-great-value-stock-right-now?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_2-2973438
Puma Biotechnology, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934401-puma-biotechnology-inc-2026-q2-results-earnings-call-presentation
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
August 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2971131/pbyi-q2-earnings-sales-beat-estimates-2026-guidance-raised?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2971131

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$28.77 +1.44 (+5.27%)
Closing price 10/20/2026 04:00 PM Eastern
Extended Trading
$28.50 -0.27 (-0.94%)
As of 10/20/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Puma Biotechnology stock logo

Puma Biotechnology NASDAQ:PBYI

$10.76 +0.55 (+5.39%)
Closing price 10/20/2026 04:00 PM Eastern
Extended Trading
$10.76 +0.00 (+0.01%)
As of 10/20/2026 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas